Dana Al Rijjal, Ying Liu, Mi Lai, Youchen Song, Zahra Danaei, Anne Wu, Haneesha Mohan, Li Wei, Francisco J Schopfer, Feihan F Dai, Michael B Wheeler
Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes, and pancreatic beta cell function are not well understood. In the present study, mice were treated with Vascepa or Lovaza for one week prior to six weeks of high-fat diet feeding. Vascepa but not Lovaza led to reduced insulin resistance, reduced fasting insulin and glucose, and improved glucose intolerance...
August 20, 2021: IScience